- organizations:Alcon, Inc.
Business
Alcon purchases majority stake in Aurion Biotech
Company replaces CEO and founder Greg Kunst, gaining access to groundbreaking CED cell therapy with plans for phase 3 clinical trials expected later this year.
Business
Alcon to acquire Lensar and its next-gen FLACS portfolio
Deal includes the ALLY Robotic Cataract Laser System, the first FDA-cleared platform to enable femtosecond-laser-assisted cataract surgery.
Products
Alcon launches Systane Pro PF drops for dry eye
Over-the-counter artificial tear is marketed as the “longest lasting eye drop” in the company’s SYSTANE portfolio.
Products
Alcon launches Voyager DSLT in the US
Device is the first and only FDA-cleared DSLT laser for glaucoma to deliver laser energy via a non-contact approach through the cornea.
Events
Eyecare companies offering support to LA wildfire victims
Industry leaders such as CooperVision, Alcon, Bausch + Lomb, and EssilorLuxottica are providing supplies and services to optometrists and residents in need.
Products
Alcon voluntarily recalls Systane Lubricant Eye Drops Ultra PF
Late last month, the FDA reported a potential risk for fungal contamination associated with one lot of the preservative-free eye drops.
Products
Alcon unveils Total30 for Astigmatism expanded parameters
New additions to the first and only reusable monthly lens feature key technologies for optimal comfort and a 2.75D cylinder.
Products
Alcon unveils Precision7 one-week replacement contact lens
Marketed as the closest to a daily disposable lens, this new line of lenses is available in toric and spheric options.
Products
Alcon debuts rebranded DSLT device and surgical products
Company offers a sneak peek of its newly-named Voyager DSLT and two gas delivery system systems for retinal detachments—plus clinical updates on a new DED treatment.
Business
Alcon innovator program identifies contact lens market needs
Inaugural initiative recruits ECPs to collect patient feedback and address top barriers influencing lens wear outcomes.
Products
Alcon program guides clinical practices on advanced technology
Designed for surgeons and staff, the Accelerator program targets patient-focused outcomes for advanced technology IOL recommendations.
Events
Experts weigh in on key trends in anterior segment innovations
Ophthalmic leaders cover market opportunities, bridging the gap between physicians and industry, as well as premium patient outcomes for the future.
Business
Alcon officially acquires BELKIN Vision
Purchase involves the Israeli company’s FDA-cleared direct selective laser trabeculoplasty technology.
Products
Alcon earns FDA clearance for vitreoretinal and cataract surgery systems
UNITY Vitreoretinal Cataract and Cataract stand-alone systems expand the Alcon Vision Suite of surgical technologies.Business
Alcon is buying Belkin Vision and its contact-less SLT glaucoma device
Acquisition is estimated to be worth up to $335 million and will close in Q3 2024.
Legal
Alcon faces penalty over Sight Sciences patent infringement
Jury trial rules that Alcon willfully infringed on three Sight Sciences patents, compelling them to pay $34 million in monetary damages.
Research
Sight Sciences reports real-world data on leading MIGS devices, including OMNI Surgical System
Large-scale, comparative study also evaluated the Hydrus Microstent and iStent inject for lowering IOP in 100,000+ glaucoma patients’ eyes.
Products
Alcon debuts new contact lens ordering app
Company’s MARLO online platform has been redesigned as a portable, on-the-go system for patients and eye care practices.
Pipeline
Positive topline data reported in Alcon's phase 3 COMET trials
Pivotal studies confirm AR-15512’s safety and efficacy for treating DED.
Products